Clinical Trials in Baltimore

Showing 16381-16400 of 23,476 trials

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

NCT00287872

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving bortezomib together with thalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving bortezomib together with thalidomide works in treating patients with newly diagnosed stage II or stage III multiple myeloma.

Multiple Myeloma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins30 participantsStarted Sep 2004

Baltimore, Maryland, United States

Approved For Marketing< 1 mile

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

NCT02592941

The expanded access program will provide access to treatment with deflazacort in children, adolescent, and adult patients with DMD in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.

Duchenne Muscular Dystrophy

PTC Therapeutics

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +39 more locations

Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

Find Trials by Condition in Baltimore

Cardiovascular Improvements With MV ASV Therapy in Heart Failure

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease

Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

Prevention of Obesity in Military Communities - Fit4Duty

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

Understanding the Value of Community Vital Signs in Primary Care

A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

Telotristat Etiprate for Carcinoid Syndrome Therapy

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Third International Study on Mechanical Ventilation

Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis

Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®

Dropless vs. Standard Drops Contralateral Eye Study